Date	Event	Description
6 March 2019	New search has been performed	Search updated. Six new trials have been included (Adhikari 2007; Boopathi 2014; Dhananjaya 2014; Ezeama 2014; Modi 2014; Singh 2009) and 10 new studies were excluded (Jans 2017; Neri‐Mejia 2016; Nuamsiri 2016; Oguz Orhan 2014; Quibel 2016; Rouse 2011; Sharma 2014; Stanton 2010; Stanton 2013; Suhrabi 2013). Two studies that were included in the previous version of this review were excluded in this version as we felt that they could not be classified as either randomised or quasi‐randomised studies (Barbaro 1961; Soiva 1964).
6 March 2019	New citation required but conclusions have not changed	The overall conclusions remain unchanged. Incorporation of new evidence suggests that any benefit of oxytocin over ergot alkaloids is now uncertain with regard to blood loss, and that oxytocin may be associated with an increased risk of a prolonged second stage, with an uncertain effect on manual placental removal. Additionally, there may be a slight reduction in blood loss with oxytocin‐ergometrine compared to ergot alkaloids.